Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > IBD News - Q3?

<< Previous

Bullboard Posts

Next >>

Comment by Harper75on Sep 19, 2023 9:01am

146 Views

Post# 35643005

RE:RE:RE:RE:RE:RE:RE:IBD News - Q3?

Hey Mugsy - thanks for the detailed reply. Delays are to be expected - no arguments here. I was calling out any Corporate update should be be able to forecast accuratly 60-90days out with more uncertainty the further out the timeline.

Perhaps I'm overly anxious for the positive new cycle to re-start after riding this wave for too many years.

<< Previous

Bullboard Posts

Next >>

Unique Battery Metals opportunity in Quebec